Physician

Joseph P Evers, M.D.

According to 2025 Medicare claims, Joseph Evers, M.D. (NPI: 1649233289) practices hematology/oncology in the Richmond, VA market, with the plurality of this provider's patient population coming from Henrico, VA. This provider's primary affiliated billing organization is VIRGINIA CANCER INSTITUTE INCORPORATED (NPI: 1730130980; TIN: 54-1066435) and primary practice location at 23229-8605.

Evers' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 637 traditional Medicare patients, billed 42,888 HCPCS/CPT codes, and received $1,323,352 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 2,027 prescription claims across 269 beneficiaries totaling $4,884,169 in drug costs, led by Imbruvica (Ibrutinib). DME data shows 44 claims. Open Payments data shows 25 records totaling $502. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has fallen sharply in recent years, from $1,725,070 to $1,323,352. In contrast, Part D prescription costs have risen steadily, from $1,557,966 to $4,884,169. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,131	100,006	$1,725,070
2016	1,095	91,294	$1,693,792
2017	1,092	192,467	$3,453,715
2018	1,171	180,567	$3,017,747
2019	1,035	189,117	$3,196,881
2020	947	135,054	$2,954,019
2021	906	139,938	$2,969,330
2022	791	72,358	$1,737,375
2023	684	49,124	$1,211,223
2024	637	42,888	$1,323,352

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	254	2,075	$1,557,966
2016	261	2,336	$2,021,928
2017	274	2,371	$2,193,192
2018	278	2,345	$3,406,001
2019	264	2,319	$3,474,479
2020	248	1,947	$3,464,196
2021	260	1,907	$3,272,031
2022	267	1,996	$4,085,974
2023	259	2,086	$3,443,594
2024	269	2,027	$4,884,169

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	48	329	$46,184
2016	13	162	$29,530
2017	12	65	$2,262
2018	N/R	73	$6,292
2019	12	102	$6,251
2020	12	137	$8,138
2021	11	60	$3,995
2022	N/R	82	$2,985
2023	N/R	41	$1,435
2024	N/R	44	$2,017

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	74	139	$135
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	251	884	$91
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	373	588	$62
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	274	447	$12
96372	Injection of drug or substance under skin or into muscle	56	150	$10

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Imbruvica	Ibrutinib	71	2,098	$1,046,283
Pomalyst	Pomalidomide	48	1,337	$938,785
Revlimid	Lenalidomide	38	1,064	$596,934
Jakafi	Ruxolitinib Phosphate	39	1,170	$455,560
Calquence	Acalabrutinib Maleate	36	1,080	$426,040

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
L8000	Breast prosthesis, mastectomy bra, without integrated breast prosthesis form, any size, any type	N	N/R	13	$1,087
J8530	Cyclophosphamide; oral, 25 mg	N	N/R	16	$648
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	15	$282

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	25	$502	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Joseph P. Evers, M.D.?

Tedicare shows public-source Medicare data for Joseph P. Evers, M.D. (NPI 1649233289), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Joseph P. Evers, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Joseph P. Evers, M.D.?

Joseph P. Evers, M.D. is linked to VIRGINIA CANCER INSTITUTE INCORPORATED (billing NPI 1730130980) in the available physician profile data.

Does Joseph P. Evers, M.D. have Open Payments data?

Joseph P. Evers, M.D. has 25 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.